Audentes Therapeutics (NASDAQ:BOLD) has been assigned a $37.00 price objective by equities research analysts at HC Wainwright in a note issued to investors on Thursday, January 4th. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential downside of 2.17% from the stock’s current price.

Other equities analysts have also recently issued reports about the company. Bank of America reiterated a “buy” rating and issued a $33.00 target price (up from $23.00) on shares of Audentes Therapeutics in a report on Friday, September 22nd. William Blair began coverage on Audentes Therapeutics in a report on Tuesday, October 17th. They issued an “outperform” rating and a $35.00 target price on the stock. Raymond James Financial began coverage on Audentes Therapeutics in a report on Thursday, October 12th. They issued a “market perform” rating on the stock. BMO Capital Markets began coverage on Audentes Therapeutics in a report on Tuesday, December 5th. They issued an “outperform” rating and a $35.00 target price on the stock. Finally, ValuEngine cut Audentes Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Two analysts have rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $35.00.

Shares of Audentes Therapeutics (NASDAQ BOLD) opened at $37.82 on Thursday. Audentes Therapeutics has a 52-week low of $13.90 and a 52-week high of $41.80.

Audentes Therapeutics (NASDAQ:BOLD) last issued its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.88). research analysts predict that Audentes Therapeutics will post -3.49 earnings per share for the current year.

In other news, Director Louis G. Lange sold 18,000 shares of Audentes Therapeutics stock in a transaction on Friday, December 22nd. The stock was sold at an average price of $30.88, for a total transaction of $555,840.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Mary Newman sold 10,000 shares of Audentes Therapeutics stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $26.84, for a total value of $268,400.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 36,000 shares of company stock worth $1,052,480. Company insiders own 47.30% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. raised its stake in shares of Audentes Therapeutics by 139.3% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 25,600 shares of the biotechnology company’s stock worth $490,000 after purchasing an additional 14,900 shares during the period. Perceptive Advisors LLC raised its stake in shares of Audentes Therapeutics by 10.4% during the 3rd quarter. Perceptive Advisors LLC now owns 781,309 shares of the biotechnology company’s stock worth $21,885,000 after purchasing an additional 73,809 shares during the period. New York State Common Retirement Fund raised its stake in shares of Audentes Therapeutics by 299.9% during the 2nd quarter. New York State Common Retirement Fund now owns 16,400 shares of the biotechnology company’s stock worth $314,000 after purchasing an additional 12,299 shares during the period. Mckinley Capital Management LLC Delaware bought a new stake in shares of Audentes Therapeutics during the 3rd quarter worth $1,333,000. Finally, Ardsley Advisory Partners raised its stake in shares of Audentes Therapeutics by 59.7% during the 2nd quarter. Ardsley Advisory Partners now owns 20,072 shares of the biotechnology company’s stock worth $384,000 after purchasing an additional 7,500 shares during the period. Institutional investors own 78.98% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Audentes Therapeutics (BOLD) Given a $37.00 Price Target by HC Wainwright Analysts” was originally reported by Marea Informative and is the sole property of of Marea Informative. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.mareainformativa.com/2018/01/30/hc-wainwright-analysts-give-audentes-therapeutics-bold-a-37-00-price-target-updated-updated-updated.html.

About Audentes Therapeutics

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.